Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
When Research Funding Disappears, So Does the Promise Made to Participants
A recent investigation from The Guardian (Sept. 17, 2026) is a sobering reminder of how research funding decisions ripple far beyond a grant number on a spreadsheet. What happened: A federally funded study examining Alzheimer's disease risk among roughly 600 older...
